skip to content

Cambridge Immunology Network



Professor Gordon Dougan's research focuses on the genetic analysis of host/pathogen interactions during infection, particularly those involving enteric bacteria. He has worked extensively in both academia and industry, making important contributions in the field of vaccinology where he has worked to improve vaccine delivery to poorly resourced regions.

Gordon Dougan is an expert in vaccinology/pathogenic mechanisms, specialising on the immunology of mucosal vaccines and molecular basis of infection. His group exploit genomic approaches to study host-pathogen interactions and the analysis of microbial populations.

Gordon has extensive teaching experience at both the undergraduate and postgraduate level. He has served on several editorial boards and regularly reviews manuscripts for high-impact journals. He is a consultant for industry and has founded biotechnology companies, including the single-chain antibody company VHSquared.

Gordon is a Fellow of the Royal Society, the Biology Society, the Academy of Medical Sciences and is an EMBO (European Molecular Biology Organization) member. He established the Centre for Molecular Microbiology and Infection (including a raising funding for a building) at Imperial College London and was the Board of Management representative for Pathogen Research for ten years (2004-2014) at the Sanger Institute where he is currently a Senior Group Leader.

Gordon worked for more than ten years for the multi-national pharmaceutical company, The Wellcome Foundation, which is now part of GSK. During this period he became Head of Molecular Biology, managing teams working on vaccines, humanised antibodies and scale-up systems. He contributed to the discovery of pertactin as a key protective antigen for acellular whooping cough vaccines and is now an advisor for many companies, serving as an Scientific Advisory Board (SAB) or Board member. Gordon was Chair of the SAB for Novartis Vaccines & Diagnostics for more than ten years and helped found the Novartis Vaccine Global Health Institute (NVGH).
He is currently on the board of The Hilleman Laboratories, a joint enterprise between Merck and The Wellcome Trust and has founded spin-out companies and served as a Trustee at the International Vaccine Institute in Korea. Gordon is also currently an SAB member for ICDDR-B (International Centre for Diarrhoeal Disease Research, Bangladesh) and has served as a member of several WHO (World Health Organization) Committees.


Key publications: 

Dyson ZA, Klemm EJ, Palmer S, Dougan G. Antibiotic Resistance and Typhoid. Clin Infect Dis. 2019 Mar 7;68(Supplement_2):S165-S170. doi: 10.1093/cid/ciy1111


Kumar N, Browne HP, Viciani E, Forster SC, Clare S, Harcourt K, Stares MD, Dougan G, Fairley DJ, Roberts P, Pirmohamed M, Clokie MRJ, Jensen MBF, Hargreaves KR, Ip M, Wieler LH, Seyboldt C, Norén T, Riley TV, Kuijper EJ, Wren BW, Lawley TD. Adaptation of host transmission cycle during Clostridium difficile speciation.Nat Genet. 2019 Sep;51(9):1315-1320. doi: 10.1038/s41588-019-0478-8. Epub 2019 Aug 12.


Blohmke CJ, Muller J, Gibani MM, Dobinson H, Shrestha S, Perinparajah S, Jin C, Hughes H, Blackwell L, Dongol S, Karkey A, Schreiber F, Pickard D, Basnyat B, Dougan G, Baker S, Pollard AJ, Darton TC. Diagnostic host gene signature for distinguishing enteric fever from other febrile diseases. EMBO Mol Med. 2019 Aug 30:e10431. doi: 10.15252/emmm.201910431.


Pérez-Vázquez M, Sola Campoy PJ, Ortega A, Bautista V, Monzón S, Ruiz-Carrascoso G, Mingorance J, González-Barberá EM, Gimeno C, Aracil B, Sáez D, Lara N, Fernández S, González-López JJ, Campos J, Kingsley RA, Dougan G, Oteo-Iglesias J; Spanish NDM Study Group . Emergence of NDM-producing Klebsiella pneumoniae and Escherichia coli in Spain: phylogeny, resistome, virulence and plasmids encoding blaNDM-like genes as determined by WGS. J Antimicrob Chemother. 2019 Sep 3. pii: dkz366. doi: 10.1093/jac/dkz366.


Ellington MJ, Heinz E, Wailan AM, Dorman MJ, de Goffau M, Cain AK, Henson SP, Gleadall N, Boinett CJ, Dougan G, Brown NM, Woodford N, Parkhill J, Török ME, Peacock SJ, Thomson NR. Contrasting patterns of longitudinal population dynamics and antimicrobial resistance mechanisms in two priority bacterial pathogens over 7 years in a single center. Genome Biol. 2019 Sep 2;20(1):184. doi: 10.1186/s13059-019-1785-1.


Heinz E, Ejaz H, Bartholdson Scott J, Wang N, Gujaran S, Pickard D, Wilksch J, Cao H, Haq IU, Dougan G, Strugnell RA. Resistance mechanisms and population structure of highly drug resistant Klebsiella in Pakistan during the introduction of the carbapenemase NDM-1. Sci Rep. 2019 Feb 20;9(1):2392. 


Klemm EJ, Wong VK, Dougan G. Emergence of dominant multidrug-resistant bacterial clades: Lessons from history and whole-genome sequencing. Proc Natl Acad Sci U S A. 2018; 115:12872-12877. PMID: 30559200


Britto CD, Wong VK, Dougan G, Pollard AJ. A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid. PLoS Negl Trop Dis. 2018 Oct 11;12:e0006779.


Houldcroft CJ, Beale MA, Sayeed MA, Qadri F, Dougan G, Mutreja A. Identification of novel adenovirus genotype 90 in children from Bangladesh. Microb Genom. 2018 Oct;4(10). doi: 10.1099/mgen.0.000221. Epub 2018 Sep 24.


Forbester JL, Lees EA, Goulding D, Forrest S, Yeung A, Speak A, Clare S, Coomber EL, Mukhopadhyay S, Kraiczy J, Schreiber F, Lawley TD, Hancock REW, Uhlig HH, Zilbauer M, Powrie F, Dougan G. Interleukin-22 promotes phagolysosomal fusion to induce protection against Salmonella enterica Typhimurium in human epithelial cells. Proc Natl Acad Sci U S A. 2018 115:10118-10123.


Mather AE, Phuong TLT, Gao Y, Clare S, Mukhopadhyay S, Goulding DA, Hoang NTD, Tuyen HT, Lan NPH, Thompson CN, Trang NHT, Carrique-Mas J, Tue NT, Campbell JI, Rabaa MA, Thanh DP, Harcourt K, Hoa NT, Trung NV, Schultsz C, Perron GG, Coia JE, Brown DJ, Okoro C, Parkhill J, Thomson NR, Chau NVV, Thwaites GE, Maskell DJ, Dougan G, Kenney LJ, Baker S. New Variant of Multidrug-Resistant Salmonella enterica Serovar Typhimurium Associated with Invasive Disease in Immunocompromised Patients in Vietnam. MBio. 2018 Sep 4;9(5). pii: e01056-18. doi: 10.1128/mBio.01056-18.


Wilson HJ, Khokhar F, Enoch DA, Brown NM, Ahluwalia J, Dougan G, Török ME. Point-prevalence survey of carbapenemase-producing Enterobacteriaceae and vancomycin-resistant enterococci in adult inpatients in a university teaching hospital in the UK. J Hosp Infect. 2018 100:35-39.


Britto CD, Dyson ZA, Duchene S, Carter MJ, Gurung M, Kelly DF, Murdoch DR, Ansari I, Thorson S, Shrestha S, Adhikari N, Dougan G, Holt KE, Pollard AJ. Laboratory and molecular surveillance of paediatric typhoidal Salmonella in Nepal: Antimicrobial resistance and implications for vaccine policy. PLoS Negl Trop Dis. 2018 Apr 23;12(4):e0006408. doi: 10.1371/journal.pntd.0006408. eCollection 2018 Apr.


Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, Wong VK, Dallman TJ, Nair S, Baker S, Shaheen G, Qureshi S, Yousafzai MT, Saleem MK, Hasan Z, Dougan G, Hasan R Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. MBio. 2018 9. pii: e00105-18.


Allcock S, Young EH, Holmes M, Gurdasani D, Dougan G, Sandhu MS, Solomon L, Török ME. Antimicrobial resistance in human populations: challenges and opportunities. Glob Health Epidemiol Genom. 2017 May 10;2:e4. doi: 10.1017/gheg.2017.4. eCollection 2017. Review. Erratum in: Glob Health Epidemiol Genom. 2017 Oct 27;2:e16.

Professor Gordon  Dougan
Takes PhD students
Available for consultancy


Departments and institutes: 
Person keywords: